RxDoctor Payments Data

Nikhil Agarwal, MD

Internal Medicine · Cedar Park, TXNPI 1124173513

Payments from drug & device makers

$11,236in general payments, 2019–2025

Across 31 payments — averaging $362.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$11K
  • Boston Scientific$84
  • Exact Sciences$76
  • AstraZeneca$46
  • Biotronik Inc.$41
  • Avenu Medical Inc.$33

What the payments were for

  • Speaking & faculty fees$9,35383%
  • Travel & lodging$9769%
  • Food & beverage$8628%
  • Education$460%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Phathom Pharmaceuticals, Inc.20$10,957
Boston Scientific1$84
Exact Sciences3$76
AstraZeneca4$46
Biotronik Inc.1$41
Avenu Medical Inc.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,236 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$29,536
Medicare patients
121
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$156,703
JanuviaSitagliptin Phosphate78$120,766
TrulicityDulaglutide52$94,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$43,460
EliquisApixaban45$42,971
OzempicSemaglutide31$42,956
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$39,513
LinzessLinaclotide34$36,046
Bydureon BciseExenatide Microspheres11$23,832
MounjaroTirzepatide19$22,289
JanumetSitagliptin Phos/Metformin Hcl12$20,148
MyrbetriqMirabegron20$10,665
SymbicortBudesonide/Formoterol Fumarate34$10,658
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$9,509
Breo ElliptaFluticasone/Vilanterol14$8,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$46$10,65834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →